Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT00451048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndromes
Secondary Myelodysplastic Syndromes

Interventions

DRUG: sunitinib malate

Sponsor

National Cancer Institute (NCI)